Genmab — Februar 2019

[JKY_VH]

enig, det er den helt rigtige vej at gå.

[E_L]

Rachel Gravesen‏ @RachelGravesen

Unlikely that daratumumab SC formulation will be submitted under RTOR as that program is only for sBLAs and the SC version will need to be a full BLA as it is a new formulation.

09:33 - 28 feb. 2019 vanuit Princeton Junction, NJ https://twitter.com/RachelGravesen/status/1101037575605764096

[peter12]

Ok aktier for nominelt 500000 kr svarer til 500000 aktier ? Det lyder ikke dumt

[Bulder]

Of even more importance - I think - is whether Columba can form the basis of an approval i all treatment lines or we'll have to wait for the combo data. That Columba data came this quickly is as good as a RTOR.

[Hen]

GENMAB/BOFA-ML: HÆVER ANBEFALING TIL NEUTRAL
Bank of America-Merrill Lynch har løftet sin anbefaling af Genmab til neutral fra underperform, rapporterer Bloomberg News.
Opjusteringen kommer oven på en god uge for Genmab-aktien, der sidste torsdag præsenterede overraskende stærke forventninger til 2019 og i denne uge har offentliggjort positive resultater fra et fase 3-studie med en mere patientvenlig version af kræftmidlet Darzalex.

[Hen]

Den nye version kan tages via sprøjte med en behandlingstid på bare omkring tre minutter, mens den nuværende version af Darzalex tages intravenøst over tre en halv time.
Aktien ligger torsdag yderligere 1,5 pct. højere i 1143 kr. og er over den seneste seks børsdage steget sammenlagt 13,4 pct.
/ritzau/FINANS

[E_L]

@Bulder yes, that is the big question. My guess is that we will have to wait for that data, but just as the data for Columba came so quick, I am now hoping for the additional data to also come quicker as expected.

[Vester]

@Bulder har du stillet spm til Winkel ang dette?

[E_L]

preliminary completion dates for Columba and MMY2040 are very similar, even though the latter started later

[E_L]

and we have been told a few times 'recruitment is going very fast'

[Bulder]

yes, I have a Q about this.

[E_L]

@Vester , this is what Jan said last Feb Q&A: Q: In january you started a “Study to evaluate Subcutaneous Daratumumab in
combination with Standard Multiple Myeloma Treatment Regimens”, which is a Phase
2. You already have the Phase 3 SC vs IV study; could these 2 clinical trials be the
basis for an overall approval of SC in all lines and settings?
Jan Van de Winkel: This is a good thought.

[E_L]

@Hen do you know if they changed their target price?

[Hen]

@
EL. Nej, desværre ikke.

[Sibelius]

Ser lige at Genmab havde 20 års fødselsdag forleden. Bekræfter det gamle mundheld om at selv de grimmeste børn kan komme til at se godt ud fuldt udvoksede:-)

[Vester]

thanks El, primary completion date for MMY2040 is even set to a month sooner than Columba.. Maybe that data will come sooner than expected as well

[henrik48]

@Hen...har de “hævet” til underperform eller outperform ?

[henrik48]

Undskyld...jeg har læst det forkert...beklager !

[Helge_LarsenPI-redaktør]

Hans-Henrik om Genmab: http://www.proinvestor.com/debat/76737

[Helge_LarsenPI-redaktør]

12-13 minutter inde i udsendelsen.